Pharmaceutical companies’ concerns over ‘Financial Gain & Expenditure Report’ even before it starts

November 24, 2017 Posted by Yakup

While being active in preparing for the ‘Financial Gain & Expenditure Report’ which will be implemented from 1 January 2018, pharmaceutical companies have encountered a new concern. When the report became obligated, pharmaceutical companies were worried about the report itself, b...

How much did listed pharmaceutical companies spend on SG&A expenses?

November 24, 2017 / Posted by Yakup

This year, the increase of collective selling, general & administrative(SG&A) expenses by the 3rd quarter of the year on average was 20 times higher in the KOSDAQ market than the one in the...

“Gleevec generics have no bioequivalent problem, and prescribing is a matter of the medical field”

November 24, 2017/ Posted by Yakup

The Ministry of Food and Drug Safety(MFDS) made straight that there was no problem for the Gleevec generics’ bioequivalence test in safety and efficacy, but prescribing generics over Gleevec ...

Green Cross wins largest blood product tender ever

November 24, 2017/ Posted by Yakup

Green Cross has drawn the largest exports of blood product ever. Green Cross(CEO Eun-Cheol Huh) announced on the 22nd that the company obtained an order of IV-Globulin SN(IVIG-SN) worth of USD 42....

Kwang Dong signs a Korean exclusive license agreement of female sexual desire disorder treatment

November 24, 2017/ Posted by Yakup

Kwang Dong Pharmaceutical(CEO Sung-Won Choi) announced on the 22nd that it signed a Korean exclusive license agreement of ‘bremelanotide,’ a substance candidate of novel drug developed ...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.